Abstract
When mortality from melioidosis fell sharply after multiple changes in management at an Australian hospital, doctors wanted to identify whether a new drug was responsible. But designing a trial that was ethically acceptable proved impossible
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Ethics, Medical
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Melioidosis / drug therapy*
-
Randomized Controlled Trials as Topic / ethics*
Substances
-
Granulocyte Colony-Stimulating Factor